D.E. Shaw & Co
RVMD icon

D.E. Shaw & Co’s Revolution Medicines RVMD Stock Holding History

D.E. Shaw & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
35,500
+10,500
+42% +$1.53M ﹤0.01% 2178
2026
Q1 		$2.43M Buy
+25,000
New +$2.52M ﹤0.01% 2761

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

D.E. Shaw & Co's RVMD Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Revolution Medicines (RVMD) stake by 99% in Q2 2026, selling an estimated $148M and leaving 12,400 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

D.E. Shaw & Co first reported a position in RVMD in Q1 2021 and has held it in 18 quarters since. The position peaked at $129M in Q4 2025. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • D.E. Shaw & Co held 12,400 shares of Revolution Medicines worth $2.32M as of Q2 2026.
  • D.E. Shaw & Co sold 1,009,898 Revolution Medicines shares in Q2 2026, an estimated $148M.
  • Revolution Medicines made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3071 holding.
  • D.E. Shaw & Co first reported a position in Revolution Medicines in Q1 2021 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Revolution Medicines position peaked at $129M in Q4 2025.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.